These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 24915490)

  • 1. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
    Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
    Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
    PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study.
    Voiosu T; Benguş A; Dinu R; Voiosu AM; Bălănescu P; Băicuş C; Diculescu M; Voiosu R; Mateescu B
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):273-8. PubMed ID: 25267955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of three commercial fecal calprotectin ELISA test kits used in patients with Inflammatory Bowel Disease.
    Mirsepasi-Lauridsen HC; Bachmann Holmetoft U; Ingdam Halkjær S; Angeliki Krogfelt K; Munk Petersen A
    Scand J Gastroenterol; 2016; 51(2):211-7. PubMed ID: 26359672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease.
    Gironella M; Iovanna JL; Sans M; Gil F; Peñalva M; Closa D; Miquel R; Piqué JM; Panés J
    Gut; 2005 Sep; 54(9):1244-53. PubMed ID: 15870231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
    Husain N; Tokoro K; Popov JM; Naides SJ; Kwasny MJ; Buchman AL
    J Clin Gastroenterol; 2013 Mar; 47(3):246-51. PubMed ID: 23269308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
    Becker K; Niederau C; Frieling T
    Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
    Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
    Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between fecal lactoferrin and inflammatory bowel disease.
    Dai J; Liu WZ; Zhao YP; Hu YB; Ge ZZ
    Scand J Gastroenterol; 2007 Dec; 42(12):1440-4. PubMed ID: 17852860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.